Lung cancer is the leading cause of cancer-related mortality. While the majority of lung
cancers are associated with tobacco smoke, approximately 10–15% of US lung cancers …

In the last 5 years the epidermal growth factor receptor (EGFR) has emerged as one of the
most important targets for drug development in oncology. Monoclonal antibodies targeting …

Background A clinical trial that compared erlotinib with a placebo for non–small-cell lung
cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from …

Purpose: In patients with non–small cell lung cancer (NSCLC), mutations in the epidermal
growth factor receptor (EGFR) tyrosine kinase domain have been associated with sensitivity …

Purpose Most cases of non–small-cell lung cancer (NSCLC) with dramatic responses to
gefitinib have specific activating mutations in the epidermal growth factor receptor (EGFR) …

Purpose: It was the aim of our study to establish an extensive panel of non-small cell lung
cancer (NSCLC) xenograft models useful for the testing of novel compounds and for the …

Purpose: Clinical reports about responsiveness to gefitinib treatment in patients of non-small
cell lung cancer (NSCLC) with mutations in exon 20 of epidermal growth factor receptor …

From histological and biological perspectives, lung cancer is a complex neoplasm. Although
the sequential preneoplastic changes have been defined for centrally arising squamous …

Background Patients with non-small-cell lung cancer sometimes show a dramatic clinical
response to gefitinib or erlotinib, small-molecule tyrosine kinase inhibitors (TKI) specific for …

Background Lung cancer is the most common cancer in the world. In addition to the
geographical and sex-specific differences in the incidence, mortality, and survival rates of …